Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.54 |
| ▸ | STS | P08842 | 3/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22954042 | 0.95 | KAT6A (0.57) | KAT6ASTSTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30668192 | 0.95 | KAT6A (0.57) | KAT6ASTSTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14297682 | 0.90 | ELANE (0.49) | KAT6ASTSTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL496275 | 0.87 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL28208860 | 0.87 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL10561497 | 0.87 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL29459930 | 0.87 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL8871614 | 0.86 | KAT6A (0.44) | KAT6ASTSTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2095288 | 0.85 | KAT6A (0.51) | KAT6ATAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL30117137 | 0.85 | KAT6A (0.51) | KAT6ATAS1R3TAS1R1TAS1R2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | claimed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | claimed |
| CN-105209464-A | P2x7 modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | claimed |
| CN-102149379-A | Methods of modulating hepatocyte growth factor (scatter factor) activity and small molecule modulator compositions of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP | 2011-08-10 | — | — | CN | claimed |
| CN-110290809-A | Pharmaceutical dosage form comprising TASK-1 and TASK-3 channel inhibitor and its purposes for treating respiratory disorder | 拜耳制药股份公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110114091-A | Pharmaceutical dosage form comprising TASK-1 and TASK-3 channel inhibitor and its purposes for treating respiratory disorder | 拜耳制药股份公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-105283443-B | Hete rocyclic derivatives and application thereof | 株式会社C&C新药研究所 | 2018-08-17 | — | — | CN | disclosed |
| CN-105283443-A | Heterocyclic derivatives and use thereof | C & C RES LAB | 2016-01-27 | — | — | CN | disclosed |
| CN-105209464-A | P2x7 modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| CN-105008361-A | Diazepine derivatives useful as calcium channel blockers in the treatment of pain | ABBVIE INC | 2015-10-28 | — | — | CN | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008070496-A2 | N- ( (3-BENZYL) -2, 2- (BIS-PHENYL) -PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070496-A2 | N- ( (3-BENZYL) -2, 2- (BIS-PHENYL) -PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KAT6A 388/4885STS 2533/4885TAS1R3 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.